By Evan George
Daily Journal Staff Writer
Oakland-based Kaiser Permanente will make its case in Boston federal court today for why Pfizer, Inc. should be forced to repay potentially tens of millions of dollars that the HMO spent prescribing an epilepsy drug for "off label" uses for which it proved ineffective.
Pfizer and its subsidiaries duped physicians into believing the anti-seizure drug Neurontin could treat every...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In